Related references
Note: Only part of the references are listed.Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Modelling the probability of erroneous negative lymph node staging in patients with colon cancer
Carlos Fortea-Sanchis et al.
CANCER COMMUNICATIONS (2019)
Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
Dawon Park et al.
ANNALS OF SURGICAL TREATMENT AND RESEARCH (2018)
Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study
Elizabeth M. Cespedes Feliciano et al.
CANCER (2017)
Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
Dimitrios Pectasides et al.
BMC CANCER (2015)
Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans
Sherrie L. Aspinall et al.
BMC CANCER (2015)
Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients
Dogan Uncu et al.
ONCOLOGY (2013)
Cerebral Hemorrhage, Warfarin, and Intravenous tPA The Real Risk Is Not Treating
Mark J. Alberts
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
Greg Yothers et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials
DJ Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Colon cancer survival rates with the new American Joint Committee on cancer sixth edition staging
JB O'Connell et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Share Paper
